CoChat

Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria

Open access
Popovici, Jean, Pierce-Friedrich, Lindsey, Kim, Saorin, Bin, Sophalai, Run, Vorleak, Lek, Dysoley, Hee, Kim Hor Daryl, Lee Soon-U, Lawrence, Cannon, Matthew V, Serre, David, Menard, Didier · 2019 · The Journal of Infectious Diseases

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.

Abstract

Background: Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes. Methods: We enrolled 40 patients with P. vivax malaria in northeastern Cambodia, where >17% treatment failures were previously reported. Patients were treated with CQ (30 mg/kg) and followed for 2 months, with frequent clinical examination and capillary blood sample collection for microscopy, molecular parasite detection and genotyping, and drug concentration measurements. Reinfections were prevented by relocating patients to a transmission-free area. Results: P. vivax parasites were eliminated in all patients by day 3. Genomic analyses revealed that all clones in polyclonal infections were cleared at the same rate, indicating their equal susceptibility to CQ. CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients), which were efficiently cleared by a second course of CQ treatment. Genotyping (128 SNPs barcode) and sequences of entire parasite genome (Whole-Genome Sequencing, Illumina) indicated that two thirds (6 of 8) of the recurrent parasites resulted from heterologous relapses whose 50% are from by sibling/recombinant clones. Conclusions: No evidence of CQ resistance was observed. Our data suggest that P. vivax antimalarial drug resistance is likely overestimated and that the current guidelines for clinical drug studies of P. vivax malaria need to be revised.

Overview

CoChat Summary

TL;DR

In 40 patients with PCR-confirmed *Plasmodium vivax* malaria in northeastern Cambodia, standard chloroquine cleared blood-stage parasites and no evidence of chloroquine resistance was found. Frequent recurrences occurred after drug levels fell below the 100 ng/mL threshold and were genetically consistent with relapses rather than recrudescence, suggesting prior CQ resistance estimates may be overestimated.

Key findings

  • All *P. vivax* parasites were cleared by day 3 by microscopy or day 6 by real-time PCR; parasite clearance half-lives ranged from 2 to 7 hours, except for 1 patient with an 11-hour half-life.
  • In 10 polyclonal infections among relocated patients, allele frequencies at variable positions were highly correlated before and 8 hours after CQ treatment (e.g., R² > 0.98 for all individuals between 0 and 8 hours), indicating all clones were cleared at similar rates; 9 of 10 had no SNP with a significant allele-frequency change.
  • Recurrences occurred in 24 of 40 patients; mean CQ concentration on the day of recurrence was 42.6 ng/mL (range, 10.5–102.7 ng/mL), with all but 1 patient below the 100 ng/mL resistance threshold. Ten symptomatic recurrences cleared within 48 hours after a second CQ regimen.
  • Genotyping (128 SNPs) and whole-genome sequencing indicated two thirds (6 of 8) of recurrent parasites resulted from heterologous relapses, 50% of which were from sibling/recombinant clones; candidate CQ-resistance polymorphisms were observed in >70% of CQ-susceptible isolates, indicating they are not causally associated with CQ resistance.

Methods

  • Prospective, open-label drug efficacy study in Ratanakiri Province, Cambodia, in 2014; 40 patients with real-time PCR-confirmed *P. vivax* monoinfection, aged ≥15 years, were treated with a supervised 3-day regimen of CQ (30 mg/kg); 20 patients were relocated to a malaria-transmission-free area and 20 were nonrelocated, with 2-month follow-up.
  • Follow-up included frequent clinical examinations and capillary blood sampling for microscopy, real-time PCR, CQ and N-desethyl chloroquine concentration measurement by liquid chromatography-tandem mass spectrometry, 128-SNP genotyping, and whole-genome sequencing (Illumina); parasite clearance rates were estimated with the Parasite Clearance Estimator.
  • Statistical comparisons used Mann-Whitney or Kruskal-Wallis tests for nonparametric comparisons and χ² or Fisher exact tests for proportions; genomic analyses are detailed in Appendix 1, with P < .05 considered statistically significant.

Limitations

  • Stated: the authors note the small number of patients enrolled in 2014 (8 of 46 in 2009 vs 0 of 40 in 2014; P = .02) and state that the study needs replication and validation in larger cohorts and other settings, such as high-transmission areas.
  • Stated: the genomic tools remain limited because they cannot differentiate relapse resulting from homologous parasite populations from recrudescence resulting from incomplete clearance of the primary asexual parasitemia.
  • Evident: the study was conducted at a single site with a 2-month follow-up; patients did not receive primaquine because it is not currently recommended by Cambodia’s National Malaria Control Program in the absence of available G6PD testing, so hypnozoite burden was not directly treated or measured.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/infdis/jiy484

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 17 Not checked · 51 Own results and interpretations

39 more claims

Create a free account to see all 68 claims and to verify the 23 references still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. World Health Organization, 2009, Methods for surveillance of antimalarial drug efficacy

Cited by

See all 59

Metadata

Authors
Popovici, J., Pierce-Friedrich, L., Kim, S., Bin, S., Run, V., Lek, D., Hee, K. H. D., Lee Soon-U, L., Cannon, M. V., Serre, D., & Menard, D.
Affiliations
  • Institut Pasteur (FR)
  • Genomic Medicine Institute, Cleveland Clinic, Ohio
  • Cambodia National Malaria Center (KH)
  • National University of Singapore
  • University of Maryland, Baltimore (US)
  • Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh
Venue
The Journal of Infectious Diseases
Published
2018-08-09
Volume
219
Issue
2
Pages
315-322
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2886136603
Cited by
59
References
30
Citations by year
2026: 5 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 13 · 2021: 8 · 2020: 9 · 2019: 4 · 2018: 1
FWCI
4.52
Type
journal article
Language
en
Open access
Locations
  • The Journal of Infectious Diseases (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health (R01 AI103228)
  • Case Western Reserve University (T32 A107024)
  • Institut Pasteur (2014–490)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Life Sciences › Immunology and Microbiology › Parasitology › Bird parasitology and diseases
Keywords
Plasmodium vivax, chloroquine, antimalarial drug resistance, relapse, reinfection, treatment failure, parasite genotyping, whole genome sequencing, polyclonal infection, Cambodia
MeSH terms
Whole Genome Sequencing, Adolescent, Adult, Antimalarials, Cambodia, Chloroquine, Drug Resistance, Female, Genotype, Humans, Male, Middle Aged, Plasmodium vivax, Recurrence, Malaria, Vivax, Treatment Failure, Sequence Analysis, DNA, Polymorphism, Single Nucleotide, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. https://app.cochat.ai/papers/10.1093/infdis/jiy484
The paper
Popovici, J., Pierce-Friedrich, L., Kim, S., Bin, S., Run, V., Lek, D., Hee, K. H. D., Lee Soon-U, L., Cannon, M. V., Serre, D., & Menard, D. (2019). Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiy484

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.